The labels indica, sativa and hybrid are used worldwide to steer customers towards a particular kind of high or relief. A new systematic review in the Journal of Cannabis Research finds no support for the idea that they say anything reliable about content or therapeutic effect. The authors instead want both retailers and healthcare to describe products by measured chemistry, product form, dose and route of administration.
28 reports on labels and content
The review covers peer-reviewed empirical reports published between 1 June 2011 and 1 June 2026. The search was run in PubMed/MEDLINE, Europe PMC, PubPsych, OpenAlex and ClinicalTrials.gov, supplemented by a coverage check via Elicit and citation searching.
Only reports that directly compared the labels indica, sativa or hybrid, or that used the labels in statistical models, were included. That yielded 28 reports: twelve studies of plants, product databases or composition, one animal study of marketed preparations and 15 studies of human treatment, symptom relief or related outcomes.
The authors assessed methodological problems and how directly the evidence answered the question, with separate criteria for the three types of material.
Get the week’s important news from Cannabis.se in your inbox — interesting weekend reading! 🥦✉️
Weak link between label and chemistry
Studies of plant material and product databases showed limited agreement between the labels and the genetic structure of the plants or their profiles of the major cannabinoids.
The terpene findings depended on which compound was measured and did not point in the same direction across studies. There were isolated signals linked to the labels, but no stable rule tying a label to a particular terpene profile.
Animal study with two oils
The animal study compared two oils marketed as indica and sativa respectively. The report described differences in cognitive effort between the two preparations, but the results apply to those preparations only and say nothing about the labels as such.
Mixed results in humans
In the 15 human reports, the associations between label and outcome varied. This covered symptom relief, subjective effects, behaviour and neurophysiological measures as well as adverse events.
Some associations were statistically significant, including for relief of insomnia and for effects linked to low arousal. But how well the studies adjusted for delta-9-tetrahydrocannabinol (THC) content and other potential confounders differed.
In comparisons where the researchers did not adjust for THC, it is impossible to tell whether the differences depended on the label or on the products having different potency.
Wants measured chemistry and dose instead
The authors conclude that the evidence does not support indica, sativa and hybrid as reliable clues to composition or therapeutic effect. They instead propose descriptions built on measured chemistry, product form, route of administration, dose and patient-specific safety considerations.
They also write that knowledge about terpenes and effects is still preliminary, and that it is not enough as a basis for rules on prescribing based on terpene profiles or labels.
The review is published as an early version of accepted research, citable with a permanent DOI, and may be replaced by the final version.



Sponsor: Sensi Seeds are one of Europe’s most recognized names in premium cannabis genetics, offering a wide selection of feminized, autoflowering, CBD-rich and F1 hybrid seeds for customers who want quality, consistency and choice.